Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Submits Brilinta To FDA, But Review Could Be Lengthy

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

AstraZeneca's submission of its antiplatelet drug Brilinta (ticagrelor) to FDA, announced Nov. 19, was on time for the firm's projections. Now it has to wait and see if an on-time approval is in the cards

You may also be interested in...



Is TMC's Cangrelor A CHAMPION After All?"Noise On The Line" Confounded Endpoint Data, CEO Says

Inability to pinpoint whether angioplasty patients enrolled in Phase III trials of The Medicines Company’s reversible antithrombotic cangrelor were already having a heart attack when they were randomized into the studies may have confounded endpoints in the failed program, according to CEO Clive Meanwell.

Is TMC's Cangrelor A CHAMPION After All?"Noise On The Line" Confounded Endpoint Data, CEO Says

Inability to pinpoint whether angioplasty patients enrolled in Phase III trials of The Medicines Company’s reversible antithrombotic cangrelor were already having a heart attack when they were randomized into the studies may have confounded endpoints in the failed program, according to CEO Clive Meanwell.

FDA Updates Plavix Label, Leaves Effient With Clear Advantage

FDA expands upon the warning that it discreetly slipped into the anti-clotting drug's labeling in May, with new data that clopidogrel is 50% less effective when given with Prilosec.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004302

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel